Smith Group Asset Management’s Harvard Bioscience HBIO Stock Holding History

Smith Group Asset Management’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-510	Closed	-$29K	–	431
2014 Q4	$29K	Hold	510	–	–	﹤0.01%	336
2014 Q3	$21K	Hold	510	–	–	﹤0.01%	302
2014 Q2	$23K	Buy	+510	New	+$21.4K	﹤0.01%	303

Other funds holding HBIO

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

JAM

Jupiter Asset Management London, United Kingdom $18.8B AUM 29.2% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

Smith Group Asset Management's HBIO Position: Q1 2015 in Review

Smith Group Asset Management sold out of Harvard Bioscience (HBIO) in Q1 2015, closing a stake of 510 shares — an estimated $29K sold.

Smith Group Asset Management first reported a position in HBIO in Q2 2014 and held it in 3 quarters. The position peaked at $29K in Q4 2014. 79 funds tracked by Wall St. Rank hold HBIO as of Q1 2015.

Smith Group Asset Management reported no remaining Harvard Bioscience position as of Q1 2015 after selling out during the quarter.
Smith Group Asset Management sold 510 Harvard Bioscience shares in Q1 2015, an estimated $29K.
Smith Group Asset Management first reported a position in Harvard Bioscience in Q2 2014 and held it in 3 quarters.
Smith Group Asset Management's Harvard Bioscience position peaked at $29K in Q4 2014.
79 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2015.

Based on Smith Group Asset Management's 13F filing for Q1 2015, filed 29 Apr 2015.